Reference
Master Dosage Chart
Every compound in the database with its class, common vial strengths, reported research range, cadence, route, half-life, and evidence tier. Sort or filter, then jump straight into the calculator.
Every compound in the database with its class, common vial strengths, reported research range, cadence, route, half-life, and evidence tier. Sort or filter, then jump straight into the calculator.
| Peptide | Type | Dose Range | How Often | How To Take It | Half-life | Evidence | |
|---|---|---|---|---|---|---|---|
| BPC-157 Body Protection Compound 157, PL 14736 |
Tissue Repair & Recovery | 10 mcg/kg – 500 mcg | 1× daily | Subcutaneous | ~4 h (preclinical) | Preclinical | Calculate → |
| TB-500 Thymosin Beta-4 fragment (Ac-SDKP region) |
Tissue Repair & Recovery | 500 mcg – 1000 mcg | once daily | Subcutaneous | ~2–3 h (parent Tβ4) | Preclinical | Calculate → |
| KPV Lys-Pro-Val (α-MSH 11-13) |
Tissue Repair & Recovery | 200 mcg – 500 mcg | 1× daily | Subcutaneous | Short (minutes–hours) | Preclinical | Calculate → |
| LL-37 Cathelicidin antimicrobial peptide, hCAP-18 fragment |
Immune & Anti-microbial | 100 mcg – 500 mcg | 1× daily | Subcutaneous | Short | Preclinical | Calculate → |
| GHK-Cu Copper tripeptide-1, Gly-His-Lys-Cu |
Cosmetic & Dermal | 1 mg – 3 mg | 1× daily | Subcutaneous | Short systemically | Clinical | Calculate → |
| Semaglutide GLP-1 receptor agonist |
Metabolic / Incretin | 0.25 mg – 2.4 mg | once weekly | Subcutaneous | ~7 days | Clinical | Calculate → |
| Tirzepatide Dual GIP/GLP-1 receptor agonist |
Metabolic / Incretin | 2.5 mg – 15 mg | once weekly | Subcutaneous | ~5 days | Clinical | Calculate → |
| Retatrutide LY3437943, triple GIP/GLP-1/glucagon agonist |
Metabolic / Incretin | 1 mg – 12 mg | once weekly | Subcutaneous | ~6 days | Clinical | Calculate → |
| AHK-Cu Alanine-histidine-lysine copper peptide |
Cosmetic & Dermal | 1 mg – 3 mg | 1× daily | Topical or subcutaneous | Short systemically | Limited | Calculate → |
| Humanin HN, mitochondrial-derived peptide |
Mitochondrial | 500 mcg – 2 mg | daily | Subcutaneous | Short (analogues longer) | Preclinical | Calculate → |
| Melanotan-1 Afamelanotide, MT-1, NDP-MSH |
Cosmetic & Dermal | 250 mcg – 500 mcg | daily | Subcutaneous | ~30 min (implant form is sustained release) | Clinical | Calculate → |
| Teriparatide PTH 1-34, recombinant parathyroid hormone fragment |
Endocrine & Sexual Health | 20 mcg – 40 mcg | once daily | Subcutaneous | ~1 h | Clinical | Calculate → |
| Cagrilintide Long-acting amylin analogue |
Metabolic / Incretin | 0.3 mg – 2.4 mg | once weekly | Subcutaneous | ~7–8 days | Clinical | Calculate → |
| Survodutide BI 456906, GLP-1/glucagon dual agonist |
Metabolic / Incretin | 0.6 mg – 6 mg | once weekly | Subcutaneous | ~6 days | Clinical | Calculate → |
| Mazdutide IBI362, LY3305677, GLP-1/glucagon agonist |
Metabolic / Incretin | 3 mg – 9 mg | once weekly | Subcutaneous | ~5–6 days | Clinical | Calculate → |
| AOD-9604 hGH fragment 176-191 |
Metabolic / Incretin | 300 mcg – 500 mcg | 1× daily | Subcutaneous | Short (<1 h) | Clinical | Calculate → |
| 5-Amino-1MQ 5-amino-1-methylquinolinium |
Metabolic / Incretin | 2.5 mg – 5 mg | 1× daily | Subcutaneous | Not well characterised | Preclinical | Calculate → |
| SLU-PP-332 ERR pan-agonist |
Metabolic / Incretin | 250 mcg – 500 mcg | 1× daily | Subcutaneous | Short | Preclinical | Calculate → |
| Adipotide FTPP, prohibitin-targeting peptidomimetic |
Metabolic / Incretin | — | daily ×28 d | Subcutaneous | Short | Preclinical | Calculate → |
| Ipamorelin GHRP, selective ghrelin receptor agonist |
GH Secretagogue | 100 mcg – 300 mcg | 1–2× daily | Subcutaneous | ~2 h | Preclinical | Calculate → |
| CJC-1295 (no DAC) Mod GRF 1-29, Sermorelin analogue |
GH Secretagogue | 100 mcg – 200 mcg | 1× daily | Subcutaneous | ~30 min | Preclinical | Calculate → |
| CJC-1295 DAC CJC-1295 with drug affinity complex |
GH Secretagogue | 1 mg – 2 mg | once weekly | Subcutaneous | ~6–8 days | Clinical | Calculate → |
| Sermorelin GHRH(1-29), Geref |
GH Secretagogue | 100 mcg – 500 mcg | nightly | Subcutaneous | ~10–20 min | Clinical | Calculate → |
| Tesamorelin TH9507, Egrifta |
GH Secretagogue | 1 mg – 2 mg | 1× daily | Subcutaneous | ~26–38 min | Clinical | Calculate → |
| GHRP-2 Pralmorelin, KP-102 |
GH Secretagogue | 100 mcg – 300 mcg | 1–3× daily | Subcutaneous | ~30 min | Clinical | Calculate → |
| GHRP-6 Growth hormone-releasing hexapeptide |
GH Secretagogue | 100 mcg – 300 mcg | 1–3× daily | Subcutaneous | ~20–30 min | Preclinical | Calculate → |
| Hexarelin Examorelin |
GH Secretagogue | 100 mcg – 200 mcg | 1–2× daily | Subcutaneous | ~55 min | Clinical | Calculate → |
| IGF-1 LR3 Long R3 insulin-like growth factor-1 |
Growth Factor | 20 mcg – 60 mcg | 1× daily | Subcutaneous | ~20–30 h | Preclinical | Calculate → |
| IGF-1 DES DES(1-3) IGF-1 |
Growth Factor | 50 mcg – 150 mcg | 1× daily | Subcutaneous | ~20–30 min | Preclinical | Calculate → |
| MGF Mechano Growth Factor, IGF-1Ec splice variant |
Growth Factor | 200 mcg – 400 mcg | post-training | Subcutaneous | Minutes | Preclinical | Calculate → |
| PEG-MGF PEGylated mechano growth factor |
Growth Factor | 200 mcg – 400 mcg | 2× weekly | Subcutaneous | ~48–72 h | Preclinical | Calculate → |
| Epitalon Epithalon, Ala-Glu-Asp-Gly (AEDG) |
Longevity & Bioregulator | 5 mg – 10 mg | days 1, 5, 9, 13 and 17 | Subcutaneous | Very short | Limited | Calculate → |
| Pinealon Glu-Asp-Arg (EDR) |
Longevity & Bioregulator | 1 mg – 2 mg | daily | Subcutaneous | Very short | Limited | Calculate → |
| Vilon Lys-Glu (KE) |
Longevity & Bioregulator | 1 mg – 10 mg | daily ×10 days | Subcutaneous | Very short | Limited | Calculate → |
| Livagen Lys-Glu-Asp-Ala (KEDA) |
Longevity & Bioregulator | 1 mg – 10 mg | daily ×10 days | Subcutaneous | Very short | Limited | Calculate → |
| Cartalax Ala-Glu-Asp-Gly (AED) |
Longevity & Bioregulator | 1 mg – 10 mg | daily ×10 days | Subcutaneous | Very short | Limited | Calculate → |
| Chonluten Glu-Asp-Gly (EDG) |
Longevity & Bioregulator | 1 mg – 10 mg | daily ×10 days | Subcutaneous | Very short | Limited | Calculate → |
| Testagen Lys-Glu-Asp-Gly (KEDG) |
Longevity & Bioregulator | 1 mg – 10 mg | daily ×10 days | Subcutaneous | Very short | Limited | Calculate → |
| Ovagen His-Leu-Asp-Gly (HLDG) |
Longevity & Bioregulator | 1 mg – 10 mg | daily ×10 days | Subcutaneous | Very short | Limited | Calculate → |
| Prostamax Lys-Glu-Asp-Pro (KEDP) |
Longevity & Bioregulator | 1 mg – 10 mg | daily ×10 days | Subcutaneous | Very short | Limited | Calculate → |
| Vesugen Lys-Glu-Asp (KED) |
Longevity & Bioregulator | 1 mg – 10 mg | daily ×10 days | Subcutaneous | Very short | Limited | Calculate → |
| Cortagen Ala-Glu-Asp-Pro (AEDP) |
Longevity & Bioregulator | 1 mg – 10 mg | daily ×10 days | Subcutaneous | Very short | Limited | Calculate → |
| FOXO4-DRI FOXO4-D-Retro-Inverso peptide |
Longevity & Bioregulator | 250 mcg – 500 mcg | once daily | Subcutaneous | Short | Preclinical | Calculate → |
| NAD+ Nicotinamide adenine dinucleotide |
Mitochondrial | 50 mg – 100 mg | 1× daily | Subcutaneous | Rapid clearance | Limited | Calculate → |
| MOTS-c Mitochondrial ORF of the 12S rRNA type-c |
Mitochondrial | 1 mg – 5 mg | once weekly | Subcutaneous | Short | Preclinical | Calculate → |
| SS-31 Elamipretide, Bendavia, MTP-131 |
Mitochondrial | 1 mg – 4 mg | 5× weekly (5 on, 2 off) | Subcutaneous | ~2–3 h | Clinical | Calculate → |
| Glutathione GSH, reduced glutathione |
Mitochondrial | 50 mg – 200 mg | 2–3× weekly | Subcutaneous | Short (minutes) | Clinical | Calculate → |
| Semax ACTH(4-7)-Pro-Gly-Pro |
Cognitive & Neuro | 200 mcg – 600 mcg | 1–2× daily | Subcutaneous | Short | Clinical | Calculate → |
| Selank Tuftsin analogue, Thr-Lys-Pro-Arg-Pro-Gly-Pro |
Cognitive & Neuro | 250 mcg – 750 mcg | 1–3× daily | Subcutaneous | Short | Clinical | Calculate → |
| Cerebrolysin Porcine brain-derived peptide preparation |
Cognitive & Neuro | 12 mg – 20 mg | once daily | Subcutaneous | Varies by fraction | Clinical | Calculate → |
| DSIP Delta Sleep-Inducing Peptide |
Cognitive & Neuro | 100 mcg – 300 mcg | pre-sleep | Subcutaneous | ~7–15 min | Limited | Calculate → |
| PE-22-28 Spadin analogue, TREK-1 blocker |
Cognitive & Neuro | 250 mcg – 500 mcg | 1× daily | Subcutaneous | Short | Preclinical | Calculate → |
| ARA-290 Cibinetide, EPO helix-B surface peptide |
Cognitive & Neuro | 2 mg – 4 mg | daily ×28 days | Subcutaneous | ~2 min (tissue effect far longer) | Clinical | Calculate → |
| Thymosin Alpha-1 Tα1, Thymalfasin, Zadaxin |
Immune & Anti-microbial | 0.8 mg – 3.2 mg | 2× weekly | Subcutaneous | ~2 h | Clinical | Calculate → |
| VIP Vasoactive Intestinal Peptide, Aviptadil |
Immune & Anti-microbial | 100 mcg – 200 mcg | 5× weekly (5 on, 2 off) | Subcutaneous | ~1–2 min | Clinical | Calculate → |
| PNC-27 p53-derived HDM-2 binding peptide |
Immune & Anti-microbial | 100 mcg – 500 mcg | once daily | Subcutaneous | Short | Preclinical | Calculate → |
| Melanotan II MT-2, cyclic α-MSH analogue |
Cosmetic & Dermal | 250 mcg – 500 mcg | 1× daily | Subcutaneous | ~1–2 h | Preclinical | Calculate → |
| SNAP-8 Acetyl octapeptide-3 |
Cosmetic & Dermal | — | 1–2× daily | Subcutaneous | Not established | Limited | Calculate → |
| PT-141 Bremelanotide, Vyleesi |
Endocrine & Sexual Health | 1 mg – 2 mg | as needed, max 1×/24 h | Subcutaneous | ~2.7 h | Clinical | Calculate → |
| Kisspeptin-10 Metastin 45-54, KP-10 |
Endocrine & Sexual Health | 100 mcg | 1× daily | Subcutaneous | ~4 min | Clinical | Calculate → |
| Gonadorelin GnRH, LHRH |
Endocrine & Sexual Health | 100 mcg – 200 mcg | 2× weekly | Subcutaneous | ~2–10 min | Clinical | Calculate → |
| Oxytocin Pitocin |
Endocrine & Sexual Health | 100 mcg – 500 mcg | once daily | Subcutaneous | ~1–6 min | Clinical | Calculate → |
| GLOW Blend GHK-Cu 50 mg + BPC-157 10 mg + TB-500 10 mg |
Multi-Compound Blends | 1.4 mg – 4.2 mg | 1× daily (≈1 mg GHK-Cu) | Subcutaneous | Mixed (component-dependent) | Preclinical | Calculate → |
| KLOW Blend KPV 10 mg + GHK-Cu 50 mg + BPC-157 10 mg + TB-500 10 mg |
Multi-Compound Blends | 1.6 mg – 4.8 mg | 1× daily | Subcutaneous | Mixed (component-dependent) | Preclinical | Calculate → |
| Wolverine Blend BPC-157 5 mg + TB-500 5 mg |
Multi-Compound Blends | 500 mcg – 1500 mcg | 1× daily · 250 mcg of each compound | Subcutaneous | Mixed | Preclinical | Calculate → |
| BPC-157 / KPV Blend BPC-157 10 mg + KPV 10 mg |
Multi-Compound Blends | 400 mcg – 1000 mcg | 1× daily · 200 mcg of each compound | Subcutaneous | Mixed (both short) | Preclinical | Calculate → |
| CJC-1295 / Ipamorelin Blend CJC-1295 no-DAC (Mod GRF 1-29) 5 mg + Ipamorelin 5 mg |
Multi-Compound Blends | 200 mcg – 600 mcg | 1× daily · 100 mcg of each compound | Subcutaneous | Mixed (~30 min / ~2 h) | Preclinical | Calculate → |
| TB-500 / BPC-157 / KPV Blend TB-500 10 mg + BPC-157 10 mg + KPV 10 mg |
Multi-Compound Blends | 600 mcg – 1500 mcg | 1× daily · 200 mcg of each compound | Subcutaneous | Mixed | Preclinical | Calculate → |
| Tesamorelin / Ipamorelin Blend Tesamorelin 12 mg + Ipamorelin 3 mg |
Multi-Compound Blends | 1.5 mg – 4 mg | 1× daily (1.2 mg tesa / 0.3 mg ipa) | Subcutaneous | Mixed | Preclinical | Calculate → |
| Semax / Selank Blend Semax 5 mg + Selank 5 mg |
Multi-Compound Blends | 500 mcg – 1200 mcg | 1× daily · 250 mcg of each compound | Subcutaneous | Mixed (both short) | Preclinical | Calculate → |
| Mito Blend NAD+ 100 mg + MOTS-c 10 mg + 5-Amino-1MQ 10 mg |
Multi-Compound Blends | 3 mg – 12 mg | 1× daily (0.25 mg MOTS-c / 2.5 mg NAD+) | Subcutaneous | Mixed | Preclinical | Calculate → |
| Retatrutide / Cagrilintide Blend Retatrutide 5 mg + Cagrilintide 5 mg |
Multi-Compound Blends | 1.2 mg – 4.8 mg | once weekly · 0.6 mg of each compound | Subcutaneous | Mixed (~6–8 days) | Preclinical | Calculate → |
SyringesU-100 insulin · 1 mL · 29–31G
Alcohol wipes70% isopropyl prep pads
Serum base — for topical mixesHyaluronic acid serum for mixing peptides into a serum
Electric cooler caseTSA-approved travel cooler — keeps mixed vials at fridge temperature
Storage caseHard carry case for vialsPaid affiliate links.
Ranges reflect figures reported in the cited literature. They are not recommendations, and the presence of a compound in this table is not an endorsement of its use.